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Abstract
Background
There are no data comparing the response to PI/r-based regimens in people presenting for
care with low CD4 counts or AIDS (LC).
Aim
To compare the response to LPV/r-, DRV/r- or ATV/r-based cART regimens in LC initiating
cART from ART-naive.
Methods
We included people enrolled in Icona with either CD4 counts350 cells/mm3 (low CD4-LC)
or CD4 counts200 cells/mm3 (very low CD4-VLC) and/or AIDS, starting their first PI/r-
based regimen after 2008. Initial regimens were compared by intention-to-treat: i) time to
viral failure (VF) (first of 2 consecutive VL>200 copies/mL after6 months); II) time to PI/r
discontinuation/switching for any cause (TD) and for toxicity (TDT); III) treatment failure (TF)
(VF or TD). Kaplan-Meier and Cox analyses were used.
Results
1,362 LC patients were included (DRV/r 607; ATV/r 552; LPV/r 203); 813 VLC. In a median
of 18 months (IQR:7–35), the 1-year probability of VF and TF were 2.8% (1.9–3.8) and
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21.1% (18.7–23.4). In the adjusted analysis, patients initiating ATV/r had a 53% lower
chance, and those initiating DRV/r a 61% lower chance of TD, as compared to LPV/r; the
risk of TF was more likely in people starting LPV/r. Results were similar among VLC; in this
subgroup LPV/r including regimens demonstrated a lower chance of VF.
Conclusions
We confirmed in LC a low chance of virological failure by 1 year, with small differences
according to PI/r. However, larger differences were observed when comparing longer-term
endpoints such as treatment failure. These results are important for people presenting late
for care.
Introduction
The recently published START trial has demonstrated that antiretroviral therapy (cART)
should be started as early as possible after HIV diagnosis [1]; this is based on solid clinical evi-
dence of what had up to this point only been shown in biological and observational studies [2–
3]. Altogether these findings have dramatically changed the approach to cART and recently
published guidelines are all in favour of initiation of ART as soon as possible after HIV diagno-
sis [4–7].
Nevertheless, worldwide and including in resource-rich countries, a rate ranging from 40 to
60% of patients are diagnosed when they have already an AIDS defining disease or a low CD4
count, and these individuals will not benefit from new indications on early therapy [8–9]. His-
torically, HIV-infected patients have been labelled as ‘late presenters’ for care on the basis of
the established threshold described in older versions of the treatment guidelines, e.g. individu-
als with a diagnosis of AIDS and/or CD4 counts of less than 350 cells/mm3 or individuals with
a even more advanced stage of HIV disease (a diagnosis of AIDS and/or CD4 counts of less
than 200 cells/mm3) at the time of their first presentation for ´[10]. These groups have been
extensively described in large collaborative cohort studies both in Europe and in other parts of
the world (8, 9). At present, the definition of ‘late presenters’ is no more applicable, as every-
body diagnosed with HIV should be treated independently from CD4 counts, otherwise could
be defined as ‘late presenter’. We therefore choose the definitions of ‘low CD4 counts (LC) and
very low CD4 count (VLC) to define people diagnosed with AIDS and/or CD4 count350
cells/mm3 or200 cells/mm3, respectively.
Although newer drugs belonging to the integrase inhibitors class (raltegravir, dolutegravir
and elvitegravir) as well as newer generation NNRTI (rilpivirine) are now the most commonly
used drugs included as third agents in first-line cART, darunavir/r and atazanavir/r are still
among the preferred options in most treatment guidelines, including Italian ones. Lopinavir/r,
in contrast, is now only considered as an alternative option by all Guidelines [4–7]. Neverthe-
less, ritonavir-boosted protease inhibitors (PI/r)-containing regimens remain regimens with
strong supporting evidence of clinical efficacy, for which clinicians have long term experience
in clinical use and are a still considered as first line options in persons with presumably low
adherence or in cases with missing drug resistance tests before starting cART, due to their high
genetic barrier [4–7].
Head to head randomised clinical trials comparing individual PI/r, lopinavir/ritonavir
(LPV/r), darunavir/ritonavir (DRV/r) and atazanavir/ritonavir (ATV/r) are not numerous and
none of those performed up to date could clearly demonstrate the superiority of one of these
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over the others with regards to potency in the subset of severely immunodepressed patients.
With respect to the safety profile, LPV/r has been shown to be less tolerable than the other two
and this is the main reason why it is no longer considered a preferred option [11–13]. However,
the choice of the best regimen in individuals with advanced HIV disease remains particularly
challenging. Randomized trials sufficiently powered to compare treatment response in people
with advanced disease starting PI/r-based regimens are either lacking or suffer from small sam-
ple size or short duration of follow-up [11–13].
Even if drug comparative analyses using observational data are, by nature, controversial and
conflict remains regarding whether they should performed at all, they may convey useful infor-
mation when no randomized comparison has been performed or planned. Also, patients have
generally been followed up for longer in the observational setting as compared to clinical trials
and cohorts include populations that are often selected out of randomized studies.
For these reasons, we performed an analysis of the outcomes of severely immunodepressed
patients in the ICONA cohort initiating a first cART regimen with ritonavir boosted PI-includ-
ing regimens, aiming at testing whether their response to treatment may vary according to the
type of PI/r initiated.
Methods
Patient population
ICONA Foundation Study (ICONA) is a multi-centre prospective observational study of HIV-
1-infected patients, which was set up in 1997. Eligible patients are those starting cART when
they are naive to antiretrovirals, regardless of the reason for which they had never been previ-
ously treated and of the stage of their disease. The ICONA Foundation study has been
approved by IRB of all the participating centers; sensitive data from patients are seen only in
aggregate form. All patients sign a consent form to participate in ICONA, in accordance with
the ethical standards of the committee on human experimentation and the Helsinki Declara-
tion (1983 revision). Demographic, clinical and laboratory data and information on therapy
are collected for all participants and recorded using electronic data collection [www.icona.org].
Details of the study are described elsewhere [14].
We focussed on two groups of individuals using the historical definitions of late presenters
as developed by an International Consensus:
1. diagnosis of AIDS and/or CD4 count350 cells/mm3 (low CD4 count group -LC)
2. diagnosis of AIDS and/or CD4 count200 cells/mm3 (very low CD4 count -VLC)
Within these groups, we selected individuals who initiated their initial cART regimen when
there were still ART-naïve after 31/12/2008. These initial cART had to include two nuclesoside
reverse transcriptase inhibitors (NRTIs, either tenofovir+emtricitabine (TDF/FTC) or abacavir
+lamivudine (ABC/3TC) + either ritonavir-boosted lopinavir (LPV/r), or ritonavir-boosted
atazanavir (ATV/r), or ritonavir-boosted darunavir (DRV/r). In addition, individuals had to
have at least one month of clinical follow-up to be included in the analysis.
The response to these initial regimens was compared according to the specific PI/r started
with respect of four main outcomes:
1. time to virological failure (VF) defined at time of the first of 2 consecutive VL>200 copies/
mL after6 months of ART;
2. time to treatment discontinuation/switching of the PI/r component of the regimen regard-
less of the reason (TD) and
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3. discontinuation because of toxicity (TDT);
4. treatment failure (TF) defined as time to VF or to discontinuation/switching of the PI/r
component of the regimen.
All causes of discontinuation are collected in the ICONA database as reported by the treat-
ing physician. In particular, clinicians are asked to report for each single drug which was the
main reason for discontinuing it. These reasons include the broad categories of simplification
(defined either as the reduction of drugs included in the regimen or the decrease in daily doses
or pills), intolerance, toxicity, failure (either virological, immunological or clinical), non-adher-
ence, planned interruption (including structured treatment interruption, end of pregnancy and
medical decision) and other causes (including patients decision, pregnancy, enrolment or end-
ing of a clinical trial and drug-drug interaction).
The main exposure of interest was the specific PI/r initiated and a separate Cox regression
model was fitted for the risk of VF, TD, TDT, and TF. The same set of potential confounders
were considered for all four models which included: age, gender, comorbidities, calendar year
of starting cART, nadir lymphocyte T CD4+ cell count, HIV-RNA plasma level at cART initia-
tion, whether TDF/FTC or ABC/3TC were used in the initial regimen.
Statistical analysis
The main characteristics of the two study populations (LC and VLC) have been described and
compared according to the initial PI/r started. Prevalence in the categorical variables has been
compared across the strata using a chi-square test. Continuous variables have been compared
using non-parametric tests.
The response to initial regimen was compared using an intention-to-treat analysis with
respect to the four main outcomes described in the previous paragraph (i.e. patients were allo-
cated to their initial PI/r regardless of subsequent treatment switches).
Standard survival analysis by Kaplan-Meier (KM) curves and Cox regression models was
used; KM estimates with 95% confidence intervals at 1 and 3 years from cART initiation were
computed and KM curves shown; unadjusted and adjusted relative hazards (RH) were com-
puted and reported. Confounding was addressed by standard multivariable modelling includ-
ing potential confounders in the adjusted models. Cox regression models were further
stratified for clinical site of enrolment. All analyses have been performed using SAS version 9.4.
Results
A total of 1,362 LC patients fulfilling the inclusion criteria were analysed: 607 (44.6%) received
DRV/r, 552 (40.5%) ATV/r and 203 (14.9%) LPV/r-including regimens. Characteristics of LC
patients according to PI-including regimen are described on Table 1: 326 (23.9%) patients were
women, 25% were non-Italian, median CD4 count was 165 cells/mmc (IQR: 59–266), median
HIV RNA log 10 copy levels/ml was 5.00 (4.40–5.49), 150 (11.0%) had a diagnosis of AIDS at
baseline. There were wide variations in demographic and clinical variables according to regi-
men: LPV/r receiving regimens individuals started cART in earlier years, were more frequently
women, less frequently infected through homosexual contacts, more frequently non Italians
(see Table 1). Subjects starting ATV/r including regimens had less frequently a AIDS diagnosis
at baseline [AIDS at baseline: 88 (14.5%) DRV/r; 26 (12.8%) LPV/r; 36(6.5%) ATV/r; p<.001].
Backbone with nucleoside pairs was mainly represented by tenofovir+emicitrabine (TDF
+FTC), given in 1207 (88.6%) of patients.
DRV/r was given mainly as QD regimen (in 489 patients-80.6%), but 87 patients (14.3%)
were given 600mg BID dosage and in 31 (5.1%) the scheduled dosage was unknown.
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Table 1. Characteristics of patients—LC group: CD4350 cells/mm3 or AIDS.
PI/r started
Characteristics DRV/r ATV/r LPV/r p-value* Total
N = 607 N = 552 N = 203 N = 1362
Gender, n(%) 0.021
Female 134 (22.1%) 128 (23.2%) 64 (31.5%) 326 (23.9%)
Mode of HIV Transmission, n(%) 0.002
IDU 42 (7.0%) 64 (11.7%) 22 (10.8%) 128 (9.5%)
Homosexual contacts 230 (38.2%) 182 (33.2%) 53 (26.1%) 465 (34.3%)
Heterosexual contacts 278 (45.8%) 271 (49.1%) 107 (52.7%) 656 (48.2%)
Other/Unknown 52 (8.6%) 32 (5.8%) 21 (10.3%) 105 (7.8%)
Nationality, n(%) 0.002
Not Italian 151 (24.9%) 133 (24.1%) 57 (28.1%) 341 (25.0%)
AIDS diagnosis, n(%) <.001
Yes 88 (14.5%) 36 (6.5%) 26 (12.8%) 150 (11.0%)
CVD diagnosis, n(%) 0.114
Yes 7 (1.2%) 2 (0.4%) 0 (0.0%) 9 (0.7%)
HBsAg, n(%) 0.638
Negative 515 (84.8%) 462 (83.7%) 178 (87.7%) 1155 (84.8%)
Positive 10 (1.6%) 13 (2.4%) 4 (2.0%) 27 (2.0%)
Not tested 82 (13.5%) 77 (13.9%) 21 (10.3%) 180 (13.2%)
HCVAb, n(%) 0.115
Negative 486 (80.1%) 434 (78.6%) 165 (81.3%) 1085 (79.7%)
Positive 52 (8.6%) 70 (12.7%) 21 (10.3%) 143 (10.5%)
Not tested 69 (11.4%) 48 (8.7%) 17 (8.4%) 134 (9.8%)
Hepatitis co-infection*, n(%) 0.077
No 453 (74.6%) 393 (71.2%) 157 (77.3%) 1003 (73.6%)
Yes 62 (10.2%) 83 (15.0%) 24 (11.8%) 169 (12.4%)
Not tested 92 (15.2%) 76 (13.8%) 22 (10.8%) 190 (14.0%)
Calendar year of baseline** <.001
Median (IQR) 2012 (2011, 2014) 2012 (2011, 2013) 2011 (2009, 2012) 2012 (2011, 2013)
Age, years 0.182
Median (IQR) 40 (33, 49) 39 (32, 47) 39 (33, 47) 39 (33, 47)
CD4 count nadir, cells/mmc <.001
Median (IQR) 131 (42, 248) 212 (99, 285) 150 (58, 246) 165 (59, 266)
CD8 count, cells/mmc 0.002
Median (IQR) 675 (441, 1001) 739 (514, 1151) 758 (513, 1147) 708 (483, 1068)
Viral load at first cART, log10 copies/mL 0.008
Median (IQR) 5.07 (4.43, 5.55) 4.89 (4.26, 5.42) 4.99 (4.47, 5.46) 5.00 (4.40, 5.49)
Site geographical position, n(%) <.001
North 310 (51.1%) 336 (60.9%) 99 (48.8%) 745 (54.7%)
Center 203 (33.4%) 174 (31.5%) 74 (36.5%) 451 (33.1%)
South 94 (15.5%) 42 (7.6%) 30 (14.8%) 166 (12.2%)
Diabetes, n(%) 0.049
Yes 9 (1.5%) 14 (2.5%) 0 (0.0%) 23 (1.7%)
Smoking, n(%) 0.020
No 293 (48.3%) 240 (43.5%) 103 (50.7%) 636 (46.7%)
Yes 182 (30.0%) 213 (38.6%) 61 (30.0%) 456 (33.5%)
Unknown 132 (21.7%) 99 (17.9%) 39 (19.2%) 270 (19.8%)
(Continued)
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A total of 813 of the 1,362 patients (59.7%) fulfilled the definition of presenters with very low
CD4 count (VLC); 414 (50.9%) initiated DRV/r-, 268 (33,0%) initiated ATV/r- and 131 (16.1%)
initiated LPV/r-including regimens. Differences among the treatment groups are shown in
Table 2 and mostly confirmed the differences occurring in the wider population of LC.
Over a median follow-up of 18 months (IQR:7–35), 57 LC patients (4.2%) experienced viro-
logical failure (VF), 507 (37.2%) experienced treatment discontinuation (TD), 97 (7.1%) dis-
continuation because of toxicity (TDT) and 485 (35.6%) treatment failure (TF).
The Kaplan Meier (KM) curves of reaching each of the end-points are represented in Fig
1a–1d.
Looking in detail at the different end-points, the KM estimate of VF was 2.8% (95%CI: 1.9–
3.8) at 1 year and 5.0% (95%CI: 3.6–6.4) at 3 years; there were no differences in the probability
of VF according to the PI/r of the regimen (Fig 1a; log rank test p =.0865). The KM estimate of
TD was 19.7% (95%CI: 17.5–22.0) at 1 year and 38.7% (95%CI: 35.6–41.7) at 3 years; the prob-
ability of TD was significantly higher for LPV/r-containing regimens in respect of the other
two PIs (Fig 1b; log rank test p<.0001). Looking at the probability of discontinuation of the
PI/r component of the regimen due to toxicity (Fig 1c) there were disparities according to the
PI/r regimens, with DRV/r showing the lower probability of this event and ATV/r the highest
Table 1. (Continued)
PI/r started
Characteristics DRV/r ATV/r LPV/r p-value* Total
N = 607 N = 552 N = 203 N = 1362
Total cholesterol, mg/dL 0.009
Median (IQR) 151 (123, 180) 157 (134, 182) 160 (140, 184) 155 (131, 182)
HDL cholesterol, mg/dL 0.017
Median (IQR) 36 (28, 44) 37 (31, 46) 37 (30, 47) 36 (30, 45)
Use of statins, n(%) 0.601
Yes 7 (1.2%) 4 (0.7%) 1 (0.5%) 12 (0.9%)
Use of blood pressure lowering drugs, n(%) 0.819
Yes 20 (3.3%) 21 (3.8%) 6 (3.0%) 47 (3.5%)
Time from HIV diagnosis to date of starting
cART, months
<.001
Median (IQR) 1 (1, 5) 2 (1, 25) 2 (1, 17) 2 (1, 13)
egfr (CKD_Epi formula), ml/min/1.73m2 0.927
Median (IQR) 106.7 (93.27,
117.3)
107.2 (96.61,
116.4)
107.7 (93.30,
117.8)
107.1 (94.61,
116.8)
Blood glucose, mg/dL 0.420
Median (IQR) 86 (79, 95) 87 (80, 94) 86 (79, 94) 86 (79, 94)
NRTI pair started, n(%) 0.964
Tenofovir/Emtricitabine 537 (88.5%) 489 (88.6%) 181 (89.2%) 1207 (88.6%)
Abacavir//Lamivudine 70 (11.5%) 63 (11.4%) 22 (10.8%) 155 (11.4%)
DRV dosage, n(%)
BID 87 (14.3%)
QD 489 (80.6%)
Unknown 31 (5.1%)
Follow-up, months <.001
Median (IQR) 17 (6, 32) 22 (9, 38) 15 (5, 37) 18 (7, 35)
*Chi-square or Kruskal-Wallis test as appropriate
doi:10.1371/journal.pone.0156360.t001
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Table 2. Characteristics of patients—VLC group: CD4 count less than 200 or AIDS.
PI/r started
DRV/r ATV/r LPV/r p-value* Total
N = 414 N = 268 N = 131 N = 813
Gender, n(%) 0.037
Female 89 (21.5%) 59 (22.0%) 42 (32.1%) 190 (23.4%)
Mode of HIV Transmission, n(%) 0.002
IDU 22 (5.3%) 34 (12.8%) 12 (9.2%) 68 (8.4%)
Homosexual contacts 140 (34.0%) 71 (26.7%) 30 (22.9%) 241 (29.8%)
Heterosexual contacts 207 (50.0%) 143 (53.4%) 73 (55.7%) 423 (52.0%)
Other/Unknown 43 (10.4%) 18 (6.8%) 16 (12.2%) 77 (9.5%)
Nationality, n(%) 0.001
Not Italian 112 (27.1%) 69 (25.7%) 42 (32.1%) 223 (27.4%)
AIDS diagnosis, n(%) 0.033
Yes 88 (21.3%) 36 (13.4%) 26 (19.8%) 150 (18.5%)
CVD diagnosis, n(%) 0.387
Yes 4 (1.0%) 1 (0.4%) 0 (0.0%) 5 (0.6%)
HBsAg, n(%) 0.463
Negative 353 (85.3%) 226 (84.3%) 117 (89.3%) 696 (85.6%)
Positive 7 (1.7%) 8 (3.0%) 1 (0.8%) 16 (2.0%)
Not tested 54 (13.0%) 34 (12.7%) 13 (9.9%) 101 (12.4%)
HCVAb, n(%) 0.066
Negative 334 (80.7%) 209 (78.0%) 109 (83.2%) 652 (80.2%)
Positive 31 (7.5%) 36 (13.4%) 10 (7.6%) 77 (9.5%)
Not tested 49 (11.8%) 23 (8.6%) 12 (9.2%) 84 (10.3%)
Hepatitis co-infection*, n(%) 0.020
No 314 (75.8%) 192 (71.6%) 106 (80.9%) 612 (75.3%)
Yes 38 (9.2%) 44 (16.4%) 11 (8.4%) 93 (11.4%)
Not tested 62 (15.0%) 32 (11.9%) 14 (10.7%) 108 (13.3%)
Calendar year of baseline** <.001
Median (IQR) 2012 (2011, 2014) 2012 (2011, 2013) 2011 (2009, 2012) 2012 (2011, 2013)
Age, years 0.964
Median (IQR) 41 (34, 50) 41 (34, 50) 41 (34, 49) 41 (34, 50)
CD4 count nadir, cells/mmc 0.006
Median (IQR) 68 (29, 132) 99 (40, 153) 85 (33, 150) 78 (32, 143)
CD8 count, cells/mmc 0.107
Median (IQR) 561 (343, 842) 609 (408, 955) 655 (370, 1047) 593 (370, 906)
Viral load at first cART, log10 copies/mL 0.397
Median (IQR) 5.26 (4.65, 5.72) 5.18 (4.60, 5.60) 5.09 (4.57, 5.63) 5.20 (4.61, 5.67)
Site geographical position, n(%) 0.136
North 207 (50.0%) 149 (55.6%) 61 (46.6%) 417 (51.3%)
Center 140 (33.8%) 91 (34.0%) 53 (40.5%) 284 (34.9%)
South 67 (16.2%) 28 (10.4%) 17 (13.0%) 112 (13.8%)
Diabetes, n(%) 0.084
Yes 8 (1.9%) 9 (3.4%) 0 (0.0%) 17 (2.1%)
Smoking, n(%) 0.282
No 201 (48.6%) 120 (44.8%) 64 (48.9%) 385 (47.4%)
Yes 116 (28.0%) 96 (35.8%) 39 (29.8%) 251 (30.9%)
Unknown 97 (23.4%) 52 (19.4%) 28 (21.4%) 177 (21.8%)
(Continued)
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(log rank test: p<.0001). Finally, the KM estimate of composite end-point of TF including the
probability of either VF or TD was 21.1% (95%CI: 18.7–23.4) at 1 year and 40.3% (95%CI:
37.1–43.4) at 3 years; LPV/r containing regimen showed the worse one (Fig 1d; log rank test:
p<.0001)-
In the multivariable Cox model (Table 3), taking into account the possible confounders
(age, gender, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS
diagnosis, nucleoside pair started, baseline CD4 count and viral load and year of starting
cART, and stratified by clinical center), there were no differences in the risk of VF according to
the regimen used. The adjusted risk of TD was statistically higher for LPV/r including regi-
mens: in comparison to LPV/r-, ATV/r had 53% lower chance and DRV/r 61% lower chance
to discontinue the PI component of the regimen. Looking at the risk of TDT, compared to
LPV/r, ATV/r regimens had a non significantly 71% higher chance (p = .09) and DRV/r
showed a non significantly 49% lower chance (p = .081) of discontinuing the PI because of tox-
icity. Finally, the chance of TF was significantly lower for both ATV/r (by 51%) and for DRV/r
(by 62%) as compared to LPV/r. The same results on different end-points were obtained by fit-
ting the Cox model after excluding patients given DRV/r as bid (data not shown).
Table 2. (Continued)
PI/r started
DRV/r ATV/r LPV/r p-value* Total
N = 414 N = 268 N = 131 N = 813
Total cholesterol, mg/dL 0.001
Median (IQR) 143 (117, 173) 153 (130, 177) 164 (138, 183) 149 (125, 177)
HDL cholesterol, mg/dL 0.062
Median (IQR) 33 (26, 42) 36 (29, 45) 35 (28, 43) 34 (27, 43)
Use of statins, n(%) 0.805
Yes 5 (1.2%) 2 (0.7%) 1 (0.8%) 8 (1.0%)
Use of blood pressure lowering drugs, n(%) 0.711
Yes 14 (3.4%) 8 (3.0%) 6 (4.6%) 28 (3.4%)
Time from HIV diagnosis to date of starting
cART, months
0.527
Median (IQR) 1 (0, 2) 1 (0, 2) 1 (0, 5) 1 (0, 2)
egfr (CKD_Epi formula), ml/min/1.73m2 0.784
Median (IQR) 108.5 (93.07,
117.8)
107.9 (95.00,
115.8)
107.7 (93.87,
117.3)
108.0 (93.82,
116.8)
Blood glucose, mg/dL 0.676
Median (IQR) 86 (79, 96) 88 (80, 96) 87 (78, 97) 87 (79, 96)
NRTI pair started, n(%) 0.593
Tenofovir/Emtricitabine 371 (89.6%) 246 (91.8%) 117 (89.3%) 734 (90.3%)
Abacavir//Lamivudine 43 (10.4%) 22 (8.2%) 14 (10.7%) 79 (9.7%)
DRV dosage, n(%)
BID 61 (14.7%)
QD 327 (79.0%)
Unknown 26 (6.3%)
Follow-up, months 0.076
Median (IQR) 16 (6, 31) 17 (7, 35) 13 (5, 34) 15 (6, 33)
*Chi-square or Kruskal-Wallis test as appropriate
doi:10.1371/journal.pone.0156360.t002
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When only the 813 VLC patients were included, in a median follow-up of 15 (6–33)
months, 28 patients underwent VF, 162 discontinued the PI/r of their regimen, 28 discontinued
because of toxicity and TF occurred in 167 patients. The 1 year-probability of these events was
4.3 (2.7–5.9)% for VF, 22.4 (19.4–25.5)% for TD, 3.9 (2.5–5.4)% for TDT, and 24.2 (21.0–
27.4)% for TF.
In these VLC patients, risk of VF was significantly higher for those receiving ATV/r includ-
ing regimens as compared to LPV/r, in the multivariate model. Similar to the findings among
the LC group, both ATV/r and DRV/r showed a lower chance to discontinue the PI component
of the regimen as compared to LPV/r including regimens.
DRV/r showed a significantly 69% lower chance (p = .081) of discontinuing the PI because
of toxicity as compared to LPV/r. Finally, the chance of TF was significantly lower for both
ATV/r (by 44%) and DRV/r (by 66%) as compared to LPV/r (Table 4).
Discussion
In our cohort including only severely immunodepressed patients given a first line PI/r contain-
ing therapy, we were able to demonstrate several differences in risk of virological failure, tolera-
bility and durability of the different regimens. But first of all, also in these categories of severely
immunodepressed patients, and roughly 50% with a viral load>5 log10 HIV-RNA copies/ml,
the likehood of virological failure was low, accounting for 2.8% and 4.3% by the first year in
those presenting with CD4 counts less than 350 and less than 200/mm3 or AIDS respectively.
Fig 1. Kaplan Meier curves of the probability of reaching the different end-points according to the PI/r
component of the initial cART regimen in 1362 HIV positive LC patients.
doi:10.1371/journal.pone.0156360.g001
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Further, the probability of discontinuation of the PI/r component of the regimen is of 19.7% by
one year, similar to what already published on the Icona cohort [15].
In this perspective, we did not found any differences in adjusted risk of virological failure
according to the PI/r given in those patients starting cART with CD4 counts less than or equal
to 350 cells/mm3 or AIDS. Nevertheless, looking at more advanced patients, with CD4 counts
up to 200 cells/mm3 or AIDS, LPV/r including regimens resulted to be at lower risk of virologi-
cal failure as in the multivariate model, ATV/r showed a 3.7-fold statistically significant higher
risk and DRV/r a 3.1-fold not significant higher risk.
Looking at the other endpoints, i.e. PI/r discontinuation for any causes or for toxicity and
treatment failure, we did not find different predictors according to the severity of immune
depression: the risk of discontinuing the PI/r of the regimen for any causes was higher for
patients given LPV/r as compared the other two PI/r, after adjustment for other possible pre-
dictors; limiting the end-point to those discontinuing only because of toxicity, there were no
differences in risk of this event when comparing ATV/r to LPV/r, while patients given DRV/r
including regimen were at lower risk of discontinuation for toxicity. Finally, LPV/r including
regimens were at higher risk of treatment failure as compared to the other PI/r regimens, in
both the groups of immune depressed patients.
To date there is no single trial comparing the different PI/r regimens in the population of
severely immune depressed patients. Actually, the head to head Castle trial [11] comparing
ATV/r vs LPV/r regimens, included patients with median CD4 count of 205, ranging from 2 to
Table 3. LC patients: RH of various endpoints from fitting a Cox regression analysis.
Crude and adjusted relative hazards
Crude RH (95% CI) p-value Adjusted* RH (95% CI) p-value
VL>200 copies/mL
Group
LPV/r 1.00 1.00
ATV/r 1.97 (1.11, 3.51) 0.021 1.92 (0.86, 4.28) 0.111
DRV/r 0.63 (0.32, 1.25) 0.185 1.13 (0.45, 2.85) 0.801
Discontinuation
Group
LPV/r 1.00 1.00
ATV/r 0.51 (0.40, 0.64) <.001 0.47 (0.37, 0.60) <.001
DRV/r 0.47 (0.37, 0.59) <.001 0.36 (0.28, 0.47) <.001
Discontinuation due to
toxicity
Group
LPV/r 1.00 1.00
ATV/r 1.97 (1.11, 3.51) 0.021 1.71 (0.91, 3.23) 0.095
DRV/r 0.63 (0.32, 1.25) 0.185 0.51 (0.24, 1.09) 0.081
VL>200 copies/mL or
discontinuation
Group
LPV/r 1.00 1.00
ATV/r 0.54 (0.42, 0.67) <.001 0.49 (0.39, 0.63) <.001
DRV/r 0.46 (0.36, 0.58) <.001 0.38 (0.29, 0.50) <.001
*adjusted for age, gender, nation of birth, mode of HIV transmission,hepatitis co-infection status, AIDS diagnosis, nucleoside pair started,baseline CD4
count and viral load and year of starting cARTand stratified by clinical center
doi:10.1371/journal.pone.0156360.t003
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810, cells/cmm, and was powered to demonstrate virological non inferiority between the two
regimens in a ITT analysis. A post-hoc analysis demonstrated that lower responses rates were
associated with lower baseline CD4 cell counts for the LPV/r but not for the ATV/r group [11].
The Artemis trial [12] was designed to demonstrate non inferiority of DRV/r 800/100 mg
once daily vs LPV/r 800/200 mg bid in the proportion of patients with HIV-RNA<50 copies/
ml by week 48. The median CD4 counts of the patients was of 228 (4–750) cells/cmm in the
DRV/r arm and 218 (2–714) in the LPV/r arm; a total of 42% of patients had CD4
counts<200/cmm at baseline. The trial demonstrated superiority in virologic response in
patients taken DRV/r as compared to LPV/r. Patients on DRV/r including regimens discontin-
ued less frequently the regimen because of side effects as compared to those on LPV/r.
Finally the ACTG5257 trial [13] included two PI/r regimens, ATV/r and DRV/r and one
integrase including regimen, Raltegravir (RAL) in a open label, randomised, 1:1.1 trial enrolling
1,809 participants, powered to demonstrate equivalence regarding virologic efficacy and tolera-
bility over 96 weeks. The median baseline CD4 count was of 309 cells/cmm; 41% of the popula-
tion had baseline CD4 counts>350/cmm. Over 2 years the three regimens attained high and
equivalent rates of virologic control, but ATV/r including regimens resulted in a higher discon-
tinuation due to tolerability as compared to the other two groups.
Taken together, we can argue that overall there was no major difference in virological
potency across the three PI/r in randomized controlled trials, but in case of patients with CD4
counts<200/mm3, LPV/r including regimen were less virologically potent than ATV/r ones.
Table 4. VLC patients: RH of various endpoints from fitting a Cox regression analysis.
Crude and adjusted relative hazards
Outcomes Crude RH (95% CI) p-value Adjusted* RH (95% CI) p-value
VL>200 copies/mL
Group
LPV/r 1.00 1.00
ATV/r 1.62 (0.83, 3.18) 0.159 3.70 (1.16, 11.74) 0.027
DRV/r 0.45 (0.20, 1.01) 0.054 3.10 (0.89, 10.80) 0.076
Discontinuation
Group
LPV/r 1.00 1.00
ATV/r 0.57 (0.43, 0.76) <.001 0.50 (0.37, 0.69) <.001
DRV/r 0.41 (0.31, 0.55) <.001 0.31 (0.22, 0.43) <.001
Discontinuation due to
toxicity
Group
LPV/r 1.00 1.00
ATV/r 1.62 (0.83, 3.18) 0.159 1.11 (0.51, 2.43) 0.795
DRV/r 0.45 (0.20, 1.01) 0.054 0.31 (0.12, 0.78) 0.013
VL>200 copies/mL or
discontinuation
Group
LPV/r 1.00 1.00
ATV/r 0.64 (0.48, 0.86) 0.003 0.56 (0.41, 0.79) <.001
DRV/r 0.42 (0.31, 0.57) <.001 0.34 (0.24, 0.48) <.001
*adjusted for age, gender, nation of birth, mode of HIV transmission,hepatitis co-infection status, AIDS diagnosis, nucleoside pair started,baseline CD4
count and viral load and year of starting cARTand stratified by clinical center
doi:10.1371/journal.pone.0156360.t004
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This last finding is not confirmed by our data in an observational setting, highlighting that
LPV/r including regimens resulted the more potent than both ATV/r and DRV/r (even if in
this last case not significantly different) in subjects with very low (< = 200/cmm) CD4 counts
or AIDS.
Observational data may be biased for many reasons, but they are more adherent to real life
than clinical trials. Possibly, LPV/r including regimens, to be administered twice a day and
with a double boosted ritonavir, could be more potent that the other PI/r, as forgiveness could
be less important.
Looking at discontinuation, LPV/r including regimens resulted to be those associated to
higher risk of discontinuation across both CD4 strata, confirming the data of trials [11–12],
particularly linked to the gastrointestinal complains of the double dose of ritonavir.
Also, the higher risk of discontinuing the PI component of the regimen was true also for
ATV/r as compared to DRV/r, confirming the finding of the ACTG5257 trial [13], possibly
due to hyperbilirubinemia as driver of willingness to discontinue the drug.
It is not surprising that, taking into account both efficacy, tolerability, scheduled timing of
administration and toxicities, LPV/r including regimens are those associated to higher risk of
treatment failure, accordingly to clinical trails, and actually all guidelines have downgraded
LPV/r to a second-line choice in initial cART [4–8], even if it shows a good virological outcome
also in the real life setting.
In conclusion, based on our data in a real life setting, focused on severely immunodepressed
patients, the overall efficacy and durability of the PI/r including regimens is high, with a like-
hood of only 4% and 21% of virological failure and discontinuation by one year.
New integrase including regimens, demonstrated to be at least at similar virological potency,
but with less toxicities than PI/r in the clinical trials [13, 16–17] should be compared to PI/r
including regimens in this setting of advanced patients in order to hopefully further improve
potency and durability of antiretroviral therapy.
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